Key clinical point: A physician global assessment for nonspecific lupus symptoms such as depression and sleeplessness ensures that they aren’t overlooked, and builds trust with patients.
Major finding: In the 5 months leading up to implementation of the PGA II, type II problems had treatment recommendations in patients’ charts just 53% of the time; the number rose to 89% of the time during the PGA II’s first 5 months (P = .03)
Study details: Quality improvement project.
Disclosures: There was no external funding, and the lead investigator didn’t have any disclosures.
Rogers J et al. Lupus Sci Med. 2019;6[suppl 1]: Abstract 102. doi: 10.1136/lupus-2019-lsm.102.